Almirall & Lundbeck Sign Co-promotion Agreement for Antidepressant in Italy

Almirall and Lundbeck have signed a co-promotion agreement for escitalopram, an antidepressant for the treatment of depression and anxiety disorder, in Italy.

Almirall, SpA and Lundbeck Italia, SpA announced Wednesday that they have signed a co-promotion agreement for escitalopram in Italy under the brand Cipralex?.

Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) family, indicated in treatment of depression and anxiety disorder.

"We are very pleased with this new collaboration with Lundbeck. It strengthens our Italian portfolio with a leading and growing product and allows us to leverage our CNS capabilities and expertise”, said Javier García, General Manager Almirall Italy.

"We are very happy at Lundbeck, says Ralph Fassey, General Manager of the Italian subsidiary, to have from now on w